Tailoring immunosuppressive therapy in interstitial lung diseases

Area of Science:

• Immunology
• Pulmonology
• Pharmacology

Background:

• The development of novel immunosuppressive drugs is rapidly advancing, with significant implications for respiratory medicine.
• Pulmonary disorders characterized by inflammation are increasingly targeted by new immunosuppressive agents in clinical trials.
• Optimizing immunosuppressive strategies for interstitial lung diseases (ILDs) is a key focus for future treatment.

Purpose of the Study:

• To review the molecular mechanisms of immunosuppressants relevant to interstitial lung diseases.
• To provide an update on current understanding of these agents' modes of action.
• To inform the selection of optimal therapeutic regimens for individual patients with ILDs.

Main Methods:

• Literature review of current understanding of immunosuppressant molecular mechanisms.
• Analysis of emerging data on novel immunosuppressive agents in clinical trials.
• Focus on agents relevant to the treatment of interstitial lung diseases.

Main Results:

• Leflunomide, a nucleotide synthesis inhibitor, shows effectiveness in chronic sarcoidosis.
• A growing number of immunosuppressants are available, offering diverse therapeutic options.
• Knowledge of molecular mechanisms is crucial for personalized immunosuppressive therapy.

Conclusions:

• Novel immunosuppressants are poised to play a significant role in managing ILDs.
• Understanding the specific mechanisms of action is essential for effective and individualized treatment strategies.
• The expanding armamentarium of immunosuppressants necessitates a comprehensive approach to therapy selection for ILDs.